Journal Mobile Options
Table of Contents
Vol. 67, No. 5-6, 2004
Issue release date: January 2005

ERK, PKC and PI3K/Akt Pathways Mediate Extracellular ATP and Adenosine-Induced Proliferation of U138-MG Human Glioma Cell Line

Jacques-Silva M.C. · Bernardi A. · Rodnight R. · Lenz G.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Objective: Extracellular nucleotides and nucleosides induce proliferation in a set of human glioma cell lines. In this study we investigate the signal transduction pathways involved in ATP and adenosine-mediated proliferation in U138-MG human glioma cells. Methods: Cell proliferation was accessed through [3H]thymidine incorporation, cell counting and flow cytometry. Protein phosphorylation was detected through Western blotting. Results: ATP or adenosine (100 µM) induced extracellular signal-regulated protein kinase (ERK), Akt and GSK3β phosphorylation. The increase in [3H]thymidine incorporation induced by ATP or adenosine was decreased when cells were incubated with LY 294002 (by ±90%), GF 109203X (by ±76%) or PD 098059 (by ±63%). The increase in cell numbers with ATP or adenosine was less after a 48-hour treatment of cells with ATP or adenosine plus GF 109203X (by ±66%) or LY 294002 (by ±83%). Percentage of cells in S phase was decreased in cells treated with LY 294002 plus ATP when compared to ATP- treated cells. Conclusion: Stimulation of purinergic receptors in U138-MG cells leads to cell proliferation mediated by PI3K/Akt, ERK and PKC signaling. It may be clinically important for pharmacological intervention in gliomas to associate purinergic receptor antagonists and signal transduction pathways blockers.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Avgeropoulos NG, Batchelor TT: New treatment strategies for malignant gliomas. Oncologist 1999;4:209–224.
  2. Wrensch M, Bondy ML, Wiencke J, Yost M: Environmental risk factors for primary malignant brain tumors: A review. J Neurooncol 1993;17:47–64
  3. Kleihues P, Burger PC, Scheithauer BW: The new WHO classification of brain tumors. Brain Pathol 1993;3:255–268.
  4. Holland EC: Gliomagenesis: Genetic alterations and mouse models. Nature Rev Genet 2001;2:120–129.
  5. Neary JT, Rathbone MP, Cattabeni F, Abbracchio MP, Burnstock G: Trophic actions of extracellular nucleotides and nucleosides on glial and neuronal cells. Trends Neurosci 1996;19:13–18.
  6. Ralevic V, Burnstock G: Receptors for purines and pyrimidines. Pharmacol Rev 1998;50:413–492.
  7. Neary JT, Baker L, Jorgensen SL, Norenberg MD: Extracellular ATP induces stellation and increases glial fibrillary acidic protein content and DNA synthesis in primary astrocyte cultures. Acta Neuropathol 1994;87:8–13.
  8. Neary JT, McCarthy M, Kang Y, Zuniga S: Mitogenic signaling from P1 and P2 putrinergic receptors to mitogen-activated protein kinase in human fetal astrocyte cultures. Neurosci Lett 1998;242:159–162.
  9. Morrone FB, Jacques-Silva MC, Horn AP, Bernardi A, Schwartsmann G, Rodnight R, Lenz G: Extracellular nucleotides and nucleosides induce proliferation and increase nucleoside transport in human glioma cell lines. J Neurooncol 2003;64:211–218.
  10. Bodin P, Burnstock G: Synergistic effect of acute hypoxia on flow-induced release of ATP from cultured endothelial cells. Experientia 1995;51:256–259.
  11. Aaronson SA: Growth factors and cancer. Science 1991;254:1146–1153.
  12. Bredel M, Pollack IF: The p21-Ras signal transduction pathway and growth regulation in human high-grade gliomas. Brain Res Rev 1999;29:232–249.
  13. Neary JT, Kang Y, Bu Y, Yu B, Akong K, Peters CM: Mitogenic signaling by ATP/P2Y purinergic receptors in astrocytes: Involvement of a calciumindependent protein kinase C, extracellular signal-regulated protein kinase pathway distinct from the phosphatidylinositol-specific phospholipase C/calcium pathway. J Neurosci 1999;19:4211–4220.
  14. Sharif TR, Sharif M: Overexpression of Protein Kinase C epsilon in astroglial brain tumor-derived cell lines and primary tumor samples. Int J Oncol 1999;15:237–243.
  15. Bredel M, Pollack IF: The role of protein kinase C (PKC) in the evolution and proliferation of malignant gliomas, and the application of PKC inhibition as a novel approachto anti-glioma therapy. Acta Neurochir (Wien) 1997;139:1000–1013.
  16. Cho K, Mikkelsen T, Lee YJ, Jiang F, Chopp M, Rosenblum ML: The role of protein kinase Cα in U-87 glioma invasion. Int J Dev Neurosci 1999;17:447–461.
  17. da Rocha AB, Mans DRA, Bernard EA, Ruschel C, Logullo AF, Wetmore LA, Leyva A, Schwartsmann G: Tamoxifen inhibits particulate-associated protein kinase C activity, and sensitises cultured human glioblastoma cells no to etoposide but to γ-radiation and BCNU. Eur J Cancer 1999;35:833–839.
  18. da Rocha AB, Mans DRA, Regner A, Schwartsmann G: Targeting protein kinase C: New therapeutic opportunities against high-grade malignant gliomas? Oncologist 2002;7:17–33.
  19. Stein RC, Waterfield M: PI3-kinase inhibition: A target for drug development? Mol Med Today 2000;6:347–357.
  20. Schelegel J, Piontek G, Budde B, Neff F, Kraus A: The Akt/PKB-dependent anti-apoptotic pathway and the MAPK cascade are alternatively activated in human glioblastoma multiforme. Cancer Lett 2000;158:103–108.
  21. Jacques-Silva MC, Rodnight R, Lenz G, Liao Z, Kong Q, Tran M, Kang Y, Gonzalez FA, Weisman GA, Neary JT: P2X7 receptors stimulate Akt phosphorylation in astrocytes. Br J Pharmacol 2004;141:1107–1118.

    External Resources

  22. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680–685.
  23. Peterson GL: Determination of total protein. Methods Enzymol 1983;91:95–119.
  24. Thorin-Trescases N, Ono Y, Tremblay J, Hamet P, Orlov SN: Dual effect of adenosine on vascular smooth muscle [3H]-thymidine DNA labeling: Receptor-mediated modulation of DNA synthesis and inhibition of thymidine uptake. J Vasc Res 1999;37:477–484.
  25. Lenz G, Gottfried C, Luo Z, Avruch J, Rodnight R, Nie W, Kang Y, Neary JT: P2Y purinoreceptor subtypes recruit different Mek activators in astrocytes. Br J Pharmacol 2000;129:927–936.
  26. Gendron F, Neary JT, Theiss PM, Sun GY, Gonzalez FA, Weisman GA: Mechanisms of P2X7 receptor-mediated ERK1/2 phosphorylation in human astrocytoma cells. Am J Cell Physiol: Cell Phys 2003;284:C571–C581.
  27. El-Deiry WS: Akt takes centre stage in cell-cycle deregulation. Nat Cell Biol 2001;3:E71–E73.

    External Resources

  28. Testa JR, Bellacosa A: Akt plays a central role in tumorigenesis. Proc Natl Acad Sci USA 2001;98:10983–10985.
  29. Gervitz LM, Nalbant D, Williams SC, Fowler JC: Adenosine-mediated activation of Akt/protein kinase B in the rat hippocampus in vitro and in vivo. Neurosci Lett 2002;328:175–179.
  30. Huwiler A, Rölz W, Dorsch S, Ren S, Pfeilschifter J: Extracellular ATP and UTP activate the protein kinase B/Akt cascade via the P2Y2 purinoreceptor in renal mesangial cells. Br J Pharmacol 2002;136:520–529.
  31. Cohen P, Frame S: The renaissance of GSK3β. Nat Rev Mol Cell Biol 2001;2:769–776.
  32. Simpson L, Parsons R: PTEN: Life as a tumor supressor. Exp Cell Res 2001;264:29–41.
  33. Sonoda Y, Ozawa T, Hirose Y, Aldape KD, McMahon M, Berger MS, Pieper RO: Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. Cancer Res 2001;61:4956–4960.
  34. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR: PD 098059 is a specific inhibitor of the activation of mitogen-activated kinase kinase in vitro and in vivo. J Biol Chem 1995;270:27489–27494.
  35. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR: A synthetic inhibitor of the MAPK cascade. Proc Natl Acad Sci USA 1995;92:7686–7689.
  36. Uhrbom L, Dai C, Celestino JC, Rosemblum MK, Fuller GN, Holland EC: Ink4a/Ark loss cooperate with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt. Cancer Res 2002;62:5551–5558.
  37. Vlahos CJ, Matter WF, Hui KY, Brown RF: A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 1994;269:5241–5248.
  38. Gingras AC, Raught B, Sonemberg N: Regulation of translation initiation by FRAP/mTOR. Genes Dev 2001;15:807–826.
  39. Marshall CJ: Specificity of receptor tyrosine kinase signalling – transient versus sustained extracellular-signal-regulated kinase activation. Cell 1995;80:179–185.
  40. Neary JT: MAPK cascades in cell growth and death. News Physiol Sci 1997;12:286–293.
  41. Neary JT, Whittemore SR, Zhu Q, Norenberg MD: Synergistic activation of DNA synthesis in astrocytes by fibroblast growth factor and extracellular ATP. J Neurochem 1994;63:490–494.
  42. Wink MR, Lenz G, Braganhol E, Tamajusuku ASK, Schwartsmann G, Sarkis JJF, Battastini AMO: Altered extracellular ATP, ADP and AMP catabolism in glioma cell lines. Cancer Lett 2003;198:211–218.
  43. Cook SJ, McCormick F: Kinetic and biochemical correlation between sustained p44ERK1 (44 kDa extracellular signal-regulated kinase 1) activation and lysophosphatidic acid-stimulated DNA synthesis in Rat-1 cells. Biochem J 1996;320:237–245.
  44. Meloche S, Seuwen K, Pages G, Pouyssegur J: Biphasic and sinergistic activation of p44mapk (ERK1) by growth factors: Correlation between late phase activation and mitogenicity. Mol Endocrinol 1992;6:845–854.
  45. Vouret-Craviari V, Van Obberghen-Schilling E, Scimeca JC, Van Obberghen E, Pouyssegur J: Differential activation of p44mapk (ERK1) by alpha-trombin and trombin-receptor peptide agonist. Biochem J 1993;289:209–214.
  46. Van Brocklyn JR, Letterle CA, Snyder PJ, Prior TW: Sphingosine-1-phosphate stimulates human glioma cell proliferation through Gi-coupled receptors: Role of ERK MAP kinase and phosphatidylinositol 3-kinase β. Cancer Lett 2002;181:195–204.
  47. Sellers LA, Simon J, Lunfahl TS, Cousens DJ, Humphrey PP, Barnard EA: Adenosine nucleotides acting at the human P2Y1 receptor stimulate mitogen- activated protein kinases and induce apoptosis. J Biol Chem 2001;276:16379–16390.
  48. Ueda Y, Hirai S, Osada S, Suzuki A, Mizuno K, Ohno S: Protein kinase Cδ activated the MEK/ERK pathway in a manner independent of Ras and dependent of Raf. J Biol Chem 1996;271:23512–23519.
  49. Seger R, Krebs EG: The MAPK signaling cascade. FASEB J 1995;9:726–735.
  50. Sun SH, Lin L, Hung AC, Kuo J: ATP-stimulated Ca2+ influx and phospholipase D activities of a rat brain-derived type-2 astrocyte cell line, RBA-2, are mediated through P2X7 receptors. J Neurochem 1999;73:334–343.
  51. Gliki G, Wheeler-Jones C, Zachary I: Vascular endothelial growth factor induces protein kinase C (PKC)-dependent Akt/PKB activation and phosphatidylinositol-3-kinase-mediated PKCδ phosphorylation: Role of PKC in angiogenesis. Cell Biol Int 2002;26:751–759.
  52. Bauer B, Jenny M, Fresser F, Überall F, Baier G: Akt1/PKBα is recruited to lipid rafts and activated downstream of PKC isotypes in CD3-induced T cell signalling. FEBS Lett 2003;541:155–162.
  53. Tanaka Y, Gavrielides MV, Mitsuuchi Y, Fujii T, Kazanietz MG: Protein kinase C promotes apoptosis in LNCaP prostate cancer cells through the activation of p38 MAPK and inhibition of the Akt survival pathway. J Biol Chem 2003;278:33753–33762.
  54. Motley ED, Eguchi K, Gardner C, Hicks AL, Reynolds CM, Frank GD, Mifune M, Ohba M, Eguchi S: Insulin-induced Akt activation is inhibited by angiotensin II in the vasculature through protein kinase C-α. Hypertension 2003;41:775–780.
  55. Downward J: Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 1998;10:262–267.
  56. Cantrell DA: Phosphoinositide 3-kinase signaling pathways. J Cell Sci 2001;114:1439–1445.
  57. Gao Z, Li BS, Day YJ, Linden J: A3 adenosine receptor activation triggers phosphorylation of protein kinase B and protects rat basophilic leukemia 2H3 mast cells from apoptosis. Mol Pharmacol 2001;59:76–82.
  58. Schulte G, Fredholm BB: Signaling pathway through the human adenosine A3 receptor expressed in Chinese hamster ovary cells to the extracellular-signal regulated kinase 1/2. Mol Pharmacol 2002;62:1137–1146.
  59. Cantley LC, Neel BG: New insights in to tumor supressor: PTEN supresses tumor formation by restraining the phosphoinositide 3-kinase/Akt pathway. Proc Nat Acad Sci USA 1999;96:4240–4245.
  60. Stambolic V, Suzuki A, de la Pompa J, Brothers G, Mirtsos C, Sasaki T, Ruland J, Penninger J, Siderovski D, Mak T: Negative regulation of PKB/Akt-dependent cell cell survival by the tumor supressor PTEN. Cell 1998;95:29–39.
  61. Weng LP, Brown JL, Eng C: PTEN induced apoptosis and cell cycle arrest through phosphatidylinositol-3-kinase/Akt-dependent and -independent pathways. Hum Mol Genet 2001;10:237–242.
  62. Diehl JA, Cheng M, Roussel MF, Sherr CJ: Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998;12:3499–3511.
  63. Alt JR, Cleveland JL, Hannik M, Diehl JA: Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev 2000;14:3102–3114.
  64. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR: Multiple Rasdependent phosphorylation pathways regulate Myc protein stability. Genes Dev 2000;14:2501–2514.
  65. Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE, Fuller GN: Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet 2000;25:55–57.
  66. Rajasekhar VK, Viale A, Socci ND, Wiedmann M, Hu X, Holland EC: Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol Cell 2003;12:889–901.
  67. Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, Palotie A, Inge L, Smith BL, Sawyers CL, Mischel PS: Analysis of the phosphatidilinositol 3- kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 2003;63:2742–2746.
  68. Shingu T, Yamada K, Hara N, Moritake K, Osago H, Terashima M, Uemura T, Yamasaki T, Tsuchiya M: Growth inhibition of human malignant glioma cells induced by the PI3K-specific inhibitor. J Neurosurg 2003;98:154–161.
  69. Shaw M, Cohen P: Role of protein kinase B and the MAP kinase cascade in mediating the EGF-dependent inhibition of glycogen synthase kinase 3 in Swiss 3T3 cells. FEBS Lett 1999;461:120–124.
  70. Barbero S, Bonavia R, Bajetto A, Porcile C, Pirani P, Ravetti JL, Zona GL, Spaziante R, Florio T, Schettini G: Stromal cell-derived factor 1alpha stimulates human glioblastoma cell growth through the activation of both extracellular signal-regulated kinases 1/2 and Akt. Cancer Res 2003;63:1969–1974.
  71. Sakata K, Kato S, Fox JC, Shigemori M, Morimatsu M: Autocrine signaling through Ras regulates cell survival activity in human glioma cells: potential cross-talk between Ras and the phosphatidylinositol 3-kinase-Akt pathway. J Neuropathol Exp Neurol 2002;61:975–83.
  72. Muscella A, Elia MG, Greco S, Storelli C, Marsigliante S: Activation of P2Y2 receptor induces c-fos protein through a pathway involving mitogen-activated protein kinases and phosphoinositide 3-kinases in HeLa cells. J Cell Physiol 2003;195:234–240.
  73. Jones SM, Kazlauskas A: Growth-factor-dependent mitogenesis requires two distinct phases of signaling. Nat Cell Biol 2001;3:165–172.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50